Schedule 13G ownership disclosure

ALNYLAM PHARMACEUTICALS INC COM

Security class unavailable · CUSIP: 02043Q107

Event date: 2022-08-31

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
12,816,777
Percent of class
10.7000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001422849-22-000166
Form type
SC 13G
Filer
ALNYLAM PHARMACEUTICALS, INC.
CIK
CIK 1178670
Filed
Sep 09, 2022
Reporting period
Aug 31, 2022
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub